Real programs. Predicted vs. observed.
Client identities are anonymized at their request, but every metric below is from a closed engagement with downstream clinical outcome confirmation.
- 73–93%
- Prediction accuracy range
- $2.4–16M
- Capital preserved per program
- 3–5 wks
- Typical simulation delivery
- 100%
- On-time delivery rate
Three programs across clinical simulation modalities
Select a case study to read the full simulation timeline, dose scenario rankings, predicted vs. observed outcomes, and ROI analysis.
Phase II Hepatotoxicity Failure Prediction for a Metabolic Small Molecule
Series B biotech needed to know whether their lead compound would survive Phase II liver safety monitoring before committing $18M to enrollment.
- 91%
- Predicted Phase II DILI failure probability
- 14 mo
- Trial timeline avoided
Oncology PK/PD Dose Optimization Simulation for a BTK Inhibitor Phase II
Clinical-stage oncology team needed exposure-response validated dose selection for a combination Phase II before protocol finalization.
- 3
- Dose arms reduced to 2
- 94%
- Predicted ORR at optimized dose
Autoimmune Biologic Trial Success Probability Modeling for Phase III Readiness
Mid-cap biotech needed quantified Phase III success probability for an IL-23 biologic before committing $85M to a 900-patient pivotal trial.
- 73%
- Predicted Phase III success probability
- 68%
- Observed Phase III primary endpoint success
Your program could be the next case study.
Tell us about your Phase II or Phase III decision. We will scope a 3 to 5 week simulation.